Penn Comprehensive Neuroscience Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Int Rev Neurobiol. 2011;100:151-68. doi: 10.1016/B978-0-12-386467-3.00008-X.
It has long been recognized that monoamine oxidase (MAO) inhibitors have a role in the management of Parkinson's disease (PD). The MAO-B inhibitor rasagiline has neuroprotective effects in animal models, mediated partly by its antiapoptotic activity. Rasagiline has been shown to be effective as monotherapy for early PD and as an adjunct to dopaminergic therapy. Clinical trials have also shown putative disease-modifying effects, though rasagiline's potential to alter the long-term course of PD remains controversial. Given the demonstrated benefits of rasagiline, along with its safety and tolerability profile, it has an important role to play in PD therapy.
人们早就认识到，单胺氧化酶（MAO）抑制剂在帕金森病（PD）的治疗中有一定作用。MAO-B 抑制剂雷沙吉兰在动物模型中有神经保护作用，部分是通过其抗细胞凋亡活性介导的。雷沙吉兰已被证明对早期 PD 有效，也可作为多巴胺能治疗的辅助药物。临床试验也显示了潜在的疾病修饰作用，尽管雷沙吉兰改变 PD 长期病程的潜力仍存在争议。鉴于雷沙吉兰的益处已得到证实，再加上其安全性和耐受性良好，它在 PD 治疗中具有重要作用。
